Latamoxef induced a severe coagulation disorder in older patients in China: Two case reports

J Clin Pharm Ther. 2021 Feb;46(1):227-229. doi: 10.1111/jcpt.13266. Epub 2020 Sep 19.

Abstract

What is known and objective: We present two cases of severe coagulation disorders induced by latamoxef, thereby revealing risk factors of coagulation disorder in latamoxef-treated patients.

Case summary: Two very elderly patients developed haemorrhage, and coagulation tests showed a longer prothrombin time (PT), activated partial thromboplastin time (APTT) and a high international normalized ratio (INR). Latamoxef was thought to be responsible for the coagulopathy in these patients, and coagulation disorder was relieved after vitamin-K intake.

What is new and conclusion: We report on two cases of coagulopathy in patients given latamoxef. Advanced age, deficiency in vitamin-K intake, poor nutritional status, abnormal coagulation history, ongoing anti-coagulation/anti-aggregation therapy, renal dysfunction and polypharmacy are possible contributory factors, and should be looked out for when prescribing latamoxef.

Keywords: coagulation disorder; coagulopathy; elderly; haemorrhage; latamoxef.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / adverse effects
  • Anti-Bacterial Agents / therapeutic use*
  • Blood Coagulation Disorders / blood
  • Blood Coagulation Disorders / diagnosis*
  • Blood Coagulation Tests
  • Diagnosis, Differential
  • Humans
  • International Normalized Ratio
  • Male
  • Moxalactam / administration & dosage
  • Moxalactam / adverse effects
  • Moxalactam / therapeutic use*
  • Partial Thromboplastin Time
  • Pneumonia, Bacterial / drug therapy*

Substances

  • Anti-Bacterial Agents
  • Moxalactam